These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 36243823)

  • 1. Contemporary Therapies and Future Directions in the Management of Hypertrophic Cardiomyopathy.
    Packard E; de Feria A; Peshin S; Reza N; Owens AT
    Cardiol Ther; 2022 Dec; 11(4):491-507. PubMed ID: 36243823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Revisiting Diagnosis and Treatment of Hypertrophic Cardiomyopathy: Current Practice and Novel Perspectives.
    Ottaviani A; Mansour D; Molinari LV; Galanti K; Mantini C; Khanji MY; Chahal AA; Zimarino M; Renda G; Sciarra L; Pelliccia F; Gallina S; Ricci F
    J Clin Med; 2023 Sep; 12(17):. PubMed ID: 37685777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review of Mavacamten for Obstructive Hypertrophic Cardiomyopathy and Future Directions.
    Dong T; Alencherry B; Ospina S; Desai MY
    Drug Des Devel Ther; 2023; 17():1097-1106. PubMed ID: 37064432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A systematic review of present and future pharmaco-structural therapies for hypertrophic cardiomyopathy.
    Sawan MA; Prabakaran S; D'Souza M; Behbahani-Nejad O; Gold ME; Williams BR; Bilen O
    Clin Cardiol; 2024 Jan; 47(1):e24207. PubMed ID: 38269637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Left ventricular outflow tract obstruction in hypertrophic cardiomyopathy and the impact of mavacamten.
    Mathai S; Williams L
    Ther Adv Chronic Dis; 2022; 13():20406223221136074. PubMed ID: 36407022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multi-modality management of hypertrophic cardiomyopathy.
    Rao SJ; Iqbal SB; Kanwal AS; Aronow WS; Naidu SS
    Hosp Pract (1995); 2023 Feb; 51(1):2-11. PubMed ID: 36598161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aficamten: A Breakthrough Therapy for Symptomatic Obstructive Hypertrophic Cardiomyopathy.
    Sebastian SA; Padda I; Lehr EJ; Johal G
    Am J Cardiovasc Drugs; 2023 Sep; 23(5):519-532. PubMed ID: 37526885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An evaluation of mavacamten for the treatment of symptomatic obstructive hypertrophic cardiomyopathy in adults.
    Dong T; Nissen S; Ospina S; Desai MY
    Expert Rev Cardiovasc Ther; 2023 Jan; 21(1):5-13. PubMed ID: 36522857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Obstructive hypertrophic cardiomyopathy: a review of new therapies.
    Mehra N; Ali AH; Desai MY
    Future Cardiol; 2023 Oct; 19(13):661-670. PubMed ID: 37933625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mavacamten: A Novel Agent for Hypertrophic Cardiomyopathy.
    Chase Cole J; Benvie SF; DeLosSantos M
    Clin Ther; 2024 Apr; 46(4):368-373. PubMed ID: 38508915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current and emerging pharmacotherapy for the management of hypertrophic cardiomyopathy.
    Rosenzveig A; Garg N; Rao SJ; Kanwal AK; Kanwal A; Aronow WS; Martinez MW
    Expert Opin Pharmacother; 2023; 24(12):1349-1360. PubMed ID: 37272195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Invasive therapies for symptomatic obstructive hypertrophic cardiomyopathy.
    Mehra N; Veselka J; Smedira N; Desai MY
    Prog Cardiovasc Dis; 2023; 80():46-52. PubMed ID: 37652213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evolving Strategies for the Management of Obstructive Hypertrophic Cardiomyopathy.
    Liang LW; Lumish HS; Sewanan LR; Shimada YJ; Maurer MS; Weiner SD; Clerkin KJ
    J Card Fail; 2024 Sep; 30(9):1136-1153. PubMed ID: 38777216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mavacamten, a Novel Therapeutic Strategy for Obstructive Hypertrophic Cardiomyopathy.
    Zampieri M; Argirò A; Marchi A; Berteotti M; Targetti M; Fornaro A; Tomberli A; Stefàno P; Marchionni N; Olivotto I
    Curr Cardiol Rep; 2021 Jun; 23(7):79. PubMed ID: 34081217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Promising therapies for adults with symptomatic obstructive hypertrophic cardiomyopathy: 2023 and beyond.
    Gaballa A; Jadam S; Desai MY
    Expert Opin Pharmacother; 2024 May; 25(7):915-924. PubMed ID: 38813944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular Genetic Basis of Hypertrophic Cardiomyopathy.
    Marian AJ
    Circ Res; 2021 May; 128(10):1533-1553. PubMed ID: 33983830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypertrophic Cardiomyopathy 2020.
    Kogut J; Popjes ED
    Curr Cardiol Rep; 2020 Oct; 22(11):154. PubMed ID: 33025145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medical Therapies to Improve Left Ventricular Outflow Obstruction and Diastolic Function in Hypertrophic Cardiomyopathy.
    Zhu M; Reyes KRL; Bilgili G; Siegel RJ; Lee Claggett B; Wong TC; Masri A; Naidu SS; Willeford A; Rader F
    JACC Adv; 2023 Oct; 2(8):100622. PubMed ID: 38938334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mavacamten, an Alternative to Septal Reduction Therapy for Patients with Hypertrophic Cardiomyopathy.
    Desai MY; Hajj Ali A
    Heart Int; 2023; 17(1):2-4. PubMed ID: 37456351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contemporary Natural History and Management of Nonobstructive Hypertrophic Cardiomyopathy.
    Maron MS; Rowin EJ; Olivotto I; Casey SA; Arretini A; Tomberli B; Garberich RF; Link MS; Chan RHM; Lesser JR; Maron BJ
    J Am Coll Cardiol; 2016 Mar; 67(12):1399-1409. PubMed ID: 27012399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.